Current report no. 2023/08/1

Following the completion of the appeal procedure, BS Biotechna S.A. received a positive recommendation for funding under the Competition for the development of targeted or personalised medicine based on medicinal products based on nucleic acids and small molecule compounds ABM/2022/6 for the project entitled ‘Design and development of nanoparticle-RNA based drugs to be used in anti-cancer therapy with the construction of a nanoparticle platform for targeted delivery of therapeutic nucleic acids’. The amount of funding is PLN 32,101,118.29.

Link